Cannabinoids & Autism Spectrum Disorder: This Baltimore Company Is On Track To Start Phase 2 Clinical Trial For New Treatment
Cannabinoid-focused biopharmaceutical company Greater Cannabis Company, Inc. (OTC: GCAN) has submitted a clinical trial application to the Israel Ministry of Health for approval of Phase 2 clinical trial for its novel neuropsychiatric cannabinoid therapy.
